Growth factor receptor levels are aberrantly high in diverse cancers, driving the proliferation and survival of tumor cells. Understanding the molecular basis for this aberrant elevation has profound clinical implications. Here we show that the pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) suppresses receptor tyrosine kinase (RTK) signaling output by a previously unidentified epigenetic mechanism unrelated to its previously described function as the hydrophobic motif phosphatase for the protein kinase AKT, protein kinase C, and S6 kinase. Specifically, we show that nuclearlocalized PHLPP suppresses histone phosphorylation and acetylation, in turn suppressing the transcription of diverse growth factor receptors, including the EGF receptor. These data uncover a much broader role for PHLPP in regulation of growth factor signaling beyond its direct inactivation of AKT: By suppressing RTK levels, PHLPP dampens the downstream signaling output of two major oncogenic pathways, the PI3 kinase/AKT and the Rat sarcoma (RAS)/ERK pathways. Our data are consistent with a model in which PHLPP modifies the histone code to control the transcription of RTKs.
B
inding of growth factors to receptor tyrosine kinases (RTKs) initiates a multitude of key cellular processes, including growth, proliferation, and survival (1) . Two of the major growth factoractivated pathways downstream of RTKs are the Rat sarcoma (RAS)/ERK and phosphatidylinositol-3 kinase (PI3 kinase)/protein kinase AKT pathways. Dysregulation of either pathway leads to uncontrolled cell proliferation and evasion of apoptosis, both hallmarks of cancer (2) . Amplified signaling by RTKs is associated with diverse human cancers, as a result of somatic gain-offunction mutations of the RTKs, gene amplification, or epigenetic changes that cause increased expression of these receptors (3) . Underscoring the prevalence of increased RTK levels in cancers, amplified expression of the EGF receptor (EGFR) family member human epidermal growth factor receptor 2 (HER2) is present in up to 30% of human breast cancers (4), a disease which accounts for a striking 30% of all new cancer cases in the United States each year (5) . Similarly, 30% of prostate cancers have been reported to have elevated expression of EGFR without evidence of gene amplification (6) . This increased expression of RTKs correlates with poor disease prognosis (7, 8) .
The regulation of protein expression by epigenetic mechanisms is reversible and thus is a particularly attractive target for cancer therapy (9, 10) . Covalent modifications of histones, including acetylation, phosphorylation, methylation, and ubiquitination, form a dynamic and complex "histone code" that is "written" and "erased" by histone modifiers and "read" by chromatin-remodeling complexes and transcriptional coregulators to control gene transcription (11) (12) (13) (14) . Small-molecule inhibitors of chromatin remodelers show potential as effective chemotherapeutic targets (15) . Most notably, histone deacetylases (HDACs) are of significant interest as chemotherapeutic targets (16, 17) . Phosphorylation is gaining increasing recognition as a key symbol in the histone code (18) . Collaboration between phosphorylation and acetylation/ methylation on histone tails influences a multitude of cellular processes, including transcription of target genes. For example, multiple lines of evidence support synergism between histone acetylation and phosphorylation in the induction of immediateearly genes (such as c-jun, c-fos, and c-myc) after mitogenic stimulation. Furthermore, having one modification can increase the efficiency of an enzyme catalyzing a second modification; for example, phosphorylation of histone H3 on Ser10 (H3S10) promotes Lys acetylation by the GCN5 acetyltransferase (18) (19) (20) (21) . H3S28 phosphorylation at gene promoters induces demethylation and acetylation of Lys27 (K27), thereby activating transcription of these genes (22) . Thus, phosphorylation of histones is a critical component of the histone code. Much emphasis has been placed on the kinases that modify this code (12, 18, 23) , but much less is known about the phosphatases that modify the histone code.
The pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) family of Ser/Thr phosphatases was discovered in a search to identify a phosphatase that could directly dephosphorylate and inactivate the prosurvival kinase AKT (24) . PHLPP phosphatases specifically dephosphorylate the hydrophobic motif of AKT (Ser473 in Akt1) but not the activation loop site (Thr308 in Akt1, a site phosphorylated by PDK1), and its genetic depletion, overexpression, or inhibition by small molecule inhibitors Significance This work unveils a previously unidentified function of the tumor suppressor pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) in inhibiting oncogenic signaling by suppressing the steady-state levels of receptor tyrosine kinases such as the EGF receptor. Specifically, PHLPP modifies the histone code to control the transcription of receptor tyrosine kinases. This epigenetic function can account for the upregulation of receptor tyrosine kinases in the multiple cancer types where PHLPP function is compromised. (25) has been shown to regulate the phosphorylation state of Ser473 in numerous studies (e.g., refs. [26] [27] [28] [29] [30] . The family comprises two genes: PHLPP1, which is alternatively spliced to yield PHLPP1α and PHLPP1β, and PHLPP2 (24, 31) . The expression of both PHLPP1 and PHLPP2 is commonly decreased in a large number of diverse cancers (reviewed in ref. 32) , and genetic deletion of one isoform, PHLPP1, is sufficient to cause prostate tumors in a mouse model (33) . Their down-regulation is associated with hypoxiainduced resistance to chemotherapy (34) , further underscoring their role in cancer. Consistent with their tumor-suppressive function, PHLPP1 and PHLPP2 are on chromosomal loci (18q21.33 and 16q22.3, respectively) that frequently are deleted in cancer (33) . The PHLPP2 locus is one of the most frequently deleted in breast cancer (35) , and that of PHLPP1 is one of the most highly deleted in colon cancer (36) . Recent studies have established that PHLPP1 and PHLPP2 suppress oncogenic signaling by at least two mechanisms (reviewed in ref. 37): (i) direct dephosphorylation and inactivation of the prosurvival kinase AKT, PKC (38) , and S6 kinase (39) , and (ii) direct dephosphorylation and activation of the proapoptotic kinase Mst1 (40) . Whether additional mechanisms account for the tumor-suppressive function of PHLPP is largely unexplored.
Here we report that PHLPP controls the amplitude of growth factor signaling by a previously unidentified mechanism that is independent of its direct dephosphorylation of AKT, PKC, or S6 kinase: It suppresses the steady-state levels of RTKs such as the EGFR by suppressing histone phosphorylation and acetylation and thus receptor transcription. These data reveal that PHLPP isozymes play a much broader role in blunting the cell's ability to respond to EGF and activate downstream signaling cascades: In addition to regulating individual signaling pathways (e.g., AKT and PKC), PHLPP isozymes set the amplitude of RTK signaling by serving as regulators of RTK transcription.
Results

Analysis of immortalized mouse embryonic fibroblasts (MEFs) from Phlpp1
−/− mice (in which both PHLPP1α and PHLPP1β are deleted) revealed that levels of EGFR protein are highly elevated compared with those in wild-type MEFs. Fig. 1A , catalytically inactive PHLPP1β (dead), PHLPP1β without the PH domain (ΔPH), PHLPP1β without the LLRs (ΔLRR), or PHLPP1β from which the PDZ binding motif was deleted (ΔPDZ). Domain structure of PHLPP1β (Top), which also includes a putative Ras association (RA) domain. The graph (Bottom) represents the quantification of three independent reconstitution experiments. ***P < 0.001, **P < 0.01, and *P < function of PHLPP, we confirmed that lack of PHLPP1 resulted in increased steady-state levels of PKCα (PKCα panel; see ref. 38 , which shows that phosphorylation increases the stability of PKC isozymes); reintroduction of PHLPP1β decreased the steady-state levels of PKCα in a manner that depended on the catalytic activity and presence of the PH domain (which is required for PHLPP to recognize PKC in cells) but not in the presence of the PDZ ligand (which is not required for PHLPP to recognize PKC in cells) (38) . These data reveal that PHLPP1 suppresses the steady-state levels of the EGFR by a mechanism depending on its catalytic activity and an intact LRR segment.
To ask whether PHLPP2 also controls RTK levels, we depleted PHLPP1, PHLPP2, or both in a number of normal and cancer cell lines. Depletion of either PHLPP1 or PHLPP2 by siRNA resulted in an increase in EGFR levels in the normal breast cell line MCF10A (Fig. 1B) , the glioblastoma cell line LN444 (Fig. 1C) , and the breast cancer cell line ZR-75-1 (Fig.  1D) . Similar results were observed in HeLa cells and A549 lung adenocarcinoma cells. Knockdown of both PHLPP isozymes resulted in an even greater increase in EGFR levels, with the magnitude of the increase varying with cell type. Previously we have shown that the ZR-75-1 cells contain the Leu1016Ser polymorphic variant of PHLPP2 that does not regulate AKT or PKC: Knockdown of PHLPP2 in these cells has no effect on the phosphorylation state of AKT or levels of PKC (42) . Importantly, knockdown of PHLPP2 in the ZR-75-1 cells causes a robust increase in EGFR levels and downstream ERK activation (Fig. 1D, lane 3) . Thus, the Leu1016Ser polymorphic variant maintains function toward regulation of EGFR levels. These data reveal that knockdown of either PHLPP1 or PHLPP2 causes a robust increase in the steady-state levels of EGFR and that, at least for PHLPP2, this effect is independent of the ability of PHLPP to dephosphorylate AKT directly. EGFR levels were elevated in MCF10A cells treated with shRNA against PHLPP1 compared with control, as assessed by both Western blot and immunocytochemistry of MCF10A acinar structures (Fig. 1E) .
Previously we have shown that the loss of Phlpp1 triggers neoplasia in prostate, consistent with its frequent alteration in human prostate cancer (33) . Western blot analysis revealed that steady-state levels of the EGFR were elevated in prostate samples from Phlpp1 −/− mice as compared with wild-type mice, suggesting that PHLPP regulation of EGFR levels may be integral to its tumor-suppressive function in this context (Fig. 1F  (33) . Levels of the INSR were elevated in prostates of Phlpp1 −/− mice ( Fig. 1F) and Phlpp1 −/− MEFs (Fig. 1G) ; PDGF receptor (PDGFR) also was elevated in Phlpp1 −/− MEFs (Fig. 1G) . These data are consistent with PHLPP's suppressing the levels of multiple oncogenic RTKs.
To assess whether the increased EGFR protein was localized at the plasma membrane where the EGFR signals, wild-type or Phlpp1
−/− MEFs were surface-labeled with biotin, and the amount of EGFR present in pulldowns using the biotin-reacting compound streptavidin was assessed ( Fig. 2A) . The amount of EGFR pulled down by streptavidin (and hence surface-biotinylated) was an order of magnitude higher in Phlpp1 −/− MEFs than in wild-type MEFs ( Fig To explore whether the elevated EGFR protein resulting from the depletion of PHLPP is signaling competent, we took advantage of a genetically encoded FRET-based EGFR kinase activity sensor (43) to monitor the basal (serum-starved) and agonist-dependent EGFR kinase activity in real time, in live Phospho-EGFR rel. units cells. The amplitude of EGF-stimulated EGFR tyrosine kinase activity was significantly higher in HeLa cells in which both PHLPP1 and PHLPP2 were depleted by siRNA than in control cells (Fig. 2B ). This EGF-dependent activity was reversed by the EGFR tyrosine kinase inhibitor AG1478. Because activity was reversed to the starting basal (serum-starved) level, these data suggest that there is no significant basal EGFR kinase activity, regardless of PHLPP depletion. Rather, PHLPP suppresses agonist-dependent receptor activity. We next addressed whether PHLPP altered the pharmacology of the EGFR. Treatment of either wild-type or Phlpp1 −/− MEFs with gefitinib, an active-site inhibitor of the tyrosine kinase activity of the EGFR and an effective therapy in nonsmall cell lung carcinoma (44) , resulted in identical dose-response curves (Fig.  2C) . Thus, PHLPP alters the levels but not the pharmacological profile of the EGFR.
The increased EGFR levels and activity conferred a proliferation advantage to cells: Fig. 3A shows that immortalized MEFs isolated from Phlpp1 −/− mice (filled squares) proliferated at a considerably faster rate than those isolated from wild-type mice (open squares). These immortalized MEFs likely have lost the ability to activate p53, because we previously have shown that loss of p53 is required for Phlpp1 −/− MEFs to proliferate at a higher rate than control MEFs (33) . This increased proliferation rate resulted from lack of PHLPP1 catalytic activity, because stable reintroduction of wild-type PHLPP1β (gray triangles), but not a catalytically-inactive construct of PHLPP1β (red triangles), into Phlpp1
−/− MEFs reduced the rate of proliferation to that observed in the wild-type MEFs. Pharmacological inhibitors revealed that this increased proliferation resulted in part from increased PI3 kinase signaling and in part from increased ERK signaling: The reduction in the G1/S ratio (reflecting cells entering the cell cycle at a faster rate) observed in cells depleted of both PHLPP isozymes compared with wild-type cells was decreased by approximately half in cells treated with either LY294002 to inhibit PI3 kinase/AKT or U0126 to inhibit MEK/ERK but was abolished in cells treated with both inhibitors (Fig. 3B) . In summary, these data reveal that loss of PHLPP results in an elevation of signaling-competent EGFR, which leads to amplified signaling by two downstream pathways, PI3 kinase and ERK, in turn increasing cell proliferation.
Reasoning that the increase in EGFR levels would increase downstream signaling, we focused on assessing the impact of PHLPP knockdown on the ERK pathway. Both basal and EGFdependent ERK phosphorylation was markedly enhanced in the glioblastoma cell line LN444 and the breast cancer cell line ZR-75-1 depleted of PHLPP1, PHLPP2, or both isozymes (Fig. 3 C and D; see also Fig. 1 C and D) . Analysis of the kinetics of agonist-evoked ERK phosphorylation revealed a robust increase in the amplitude of ERK phosphorylation both in LN444 cells depleted of both PHLPP1 and PHLPP2 (Fig. 3E ) and in Phlpp1 −/− MEFs (Fig. 3F) . However, the rate of subsequent dephosphorylation of ERK was not significantly different in cells with or without PHLPP (t 1/2 for dephosphorylation was 50 ± 7 and 44 ± 2 min, respectively, in LN444 cells and 26 ± 13 and 28 ± 3 min, respectively, in MEFs). Thus, PHLPP suppresses the agonistdependent phosphorylation of ERK but does not control the postactivation dephosphorylation of ERK. These data reveal that PHLPP1 and PHLPP2 suppress the activation of ERK in response to EGF, a logical consequence of their role in suppressing EGFR levels.
We next addressed whether PHLPP suppresses the steady-state levels of EGFR by (i) inhibiting its biosynthesis or (ii) promoting its degradation. To examine the rate of biosynthesis, wild-type or 
Phlpp1
−/− MEFs were incubated with medium containing 35 S-Met/ Cys, and the incorporation of radioactivity into immunoprecipitated EGFR was monitored as a function of time. Quantitative analysis of incorporated radioactivity at a band comigrating with the immunoprecipitated EGFR revealed a 2.5-fold increase in the rate of biosynthesis in cells lacking PHLPP1 (252 ± 50 cpm incorporated per minute) compared with wild-type cells (104 ± 10 cpm incorporated per minute) (Fig. 4A) . In contrast to the rate of biosynthesis, the rate of EGF-stimulated degradation of the EGFR was the same in wild-type (30 ± 17 min) and Phlpp1 −/− MEFs (30 ± 15 min) (Fig. 4B) . Similarly, the basal rate of turnover of the receptor, assessed after treatment of cells with cycloheximide to prevent protein synthesis, was not significantly different in wild-type cells (8 ± 4 h) and cells lacking PHLPP1 (11 ± 4 h) (Fig. 4C) . Given the increased rate of biosynthesis, we reasoned that mRNA levels of the EGFR might be elevated in cells lacking PHLPP1. Indeed, quantitative RT-PCR (qRT-PCR) analysis revealed a 20 ± 5-fold increase in the levels of EGFR mRNA in Phlpp1 −/− MEFs compared with wild-type MEFs; this increase was reduced twofold upon reintroduction of PHLPP1β into Phlpp1 −/− MEFs (Fig. 4D) . Importantly, EGFR mRNA was elevated in the Phlpp1 −/− mouse: EGFR mRNA was approximately twofold higher in prostates from 6-mo-old Phlpp1 −/− mice than in prostates from wild-type littermates (Fig. 4E) . Last, we examined whether the mRNA levels were elevated because of increased stability. The addition of actinomycin D to prevent mRNA transcription revealed that the rate of decay of existing mRNA was the same in wild-type and Phlpp1 −/− MEFs (Fig. 4F) . Thus, loss of PHLPP1 resulted in increased mRNA levels and an increased rate of protein translation of the EGFR, resulting in increased steady-state levels. [Note that there is not a linear correlation between mRNA and protein translation rates (45)]. Taken together, these data show that PHLPP suppresses the transcription of the EGFR.
We next used a pharmacological approach to identify targets of PHLPP that could control the transcription of RTKs and thus their steady-state levels. Pharmacological inhibitors of known PHLPP targets (including the EGFR itself) had no significant effect on the ability of PHLPP depletion to increase EGFR expression (Fig. S1) . Inhibition of PI3 kinase signaling with LY294002 (LY) (lane 3), ERK signaling with U0126 (UO) (lane 4), PKC signaling with Gö6983 (Gö) (lane 5), or EGFR tyrosine kinase signaling with AG1478 (AG) (lane 6) had no significant effect on the increased levels of EGFR in PHLPP-knockdown cells relative to untreated controls (lane 2).
The finding that PHLPP controls the transcription of the EGFR led us to ask whether nuclear localization of PHLPP is necessary for this function. Specifically, we examined whether addition of a nuclear localization signal (NLS) onto the ΔLRR construct of PHLPP, which loses the ability to regulate the EGFR, could restore regulation of the EGFR. The data in Fig. 5A show that reconstitution of Phlpp1 −/− MEFs with wild-type PHLPP1β (lane 2) reduced the EGFR level compared with vector control (lane 1), whereas reconstitution with the ΔLRR construct increased EGFR levels (lanes 3 and 4). However, a construct in which an NLS was fused to the ΔLRR effectively reduced EGFR levels (lanes 5 and 6). These findings are consistent with the LRR segment of PHLPP driving or retaining PHLPP in the nucleus, where it regulates EGFR transcription.
Given that PHLPP loss up-regulated several RTKs, we hypothesized that PHLPP could modify the histone code so as to suppress transcription. Thus, we explored the effect of PHLPP deletion on histone acetylation and histone phosphorylation. the acetylation of specific histones at specific sites in Phlpp1
MEFs compared with wild-type MEFs (Fig. 5B) . Specifically, acetylation was increased on K27 but not K9 on H3; phosphorylation was not significantly altered on S10 and S28; there was a robust increase in the double modification of S10 and K9 but not of S10 and K14. Lys acetylation was increased in H2A and H2B, but not H4; S139 phosphorylation was increased in H2A; no change in phosphorylation was noted on S14 in H2B. The increases in histone acetylation were reversed in Phlpp1 −/− MEFs in which PHLPP1β had been reintroduced (Fig. S2) . These data reveal a selective modification of the histone code by PHLPP1.
We next asked whether acetylated histones preferentially associated with the EGFR, INSR, and PDGFR promoters. ChIP assays revealed a significant increase in H3K27ac at the EGFR, PDGFR, and INSR promoters but not at the promoters of two genes whose mRNA levels are not affected by PHLPP1, Cxcl10 or Ccl4, in samples from Phlpp1 −/− MEFs as compared with wildtype MEFs (Fig. 6A) . In contrast, there was no significant difference in the H4K5ac at the EGFR promoter or control promoters, but there was increased H4K5ac at the INSR and PDGFR promoters in Phlpp1 −/− vs. wild-type MEFs. Although not detected on Western blot, there was a modest increase in H3K9ac at the EGFR promoter in Phlpp1 −/− compared with wild-type MEFs. These data are consistent with PHLPP suppressing the transcription of RTKs by regulating histone acetylation at their receptor promoters.
If PHLPP controls the transcription of RTKs, we reasoned that loss of PHLPP would result in an increase of actively transcribed RTK mRNAs. We performed a global run-on experiment, which measures actively transcribing mRNAs (46) , to show that the rate of transcription of EGFR, INSR, and PDGFR, but not the control genes 36B4, CCL4, or CXCl10, was increased significantly in Phlpp1 −/− vs. wild-type MEFs (Fig. 6B) . Last, we asked whether PHLPP1 binds to the RTK promoters. ChIP using antibodies to endogenous PHLPP1 revealed robust recruitment of PHLPP1 to the promoters of the EGFR, PDGFR, and INSR but not to the two control promoters (Fig. 6C) . Note that the data are presented as the binding observed in the wildtype cells over the Phlpp1 −/− MEFs to control for any nonspecific binding. These data demonstrate that PHLPP is actively recruited to the RTK promoters.
Discussion
The foregoing data unveil a previously unidentified mechanism by which PHLPP suppresses growth factor signaling: suppression of the steady-state levels of RTKs, notably the EGFR, by inhibiting their transcription (Fig. 7, Left) . This mechanism is distinct from the previously characterized direct dephosphorylation of histones. The graph shows the mean ± SEM of quantified acetylation or phosphorylation normalized to total histone and to wild-type control from three independent experiments; *P < 0.01 by Student t test.
AKT (Fig. 7, Right) or PKC, which is selective for the hydrophobic motif, does not occur with the Leu1016Ser polymorphic variant of PHLPP2, requires an intact PDZ ligand (for AKT) or PH domain (for PKC), and dominates under basal conditions (24, 31, 42) . In contrast, the mechanism regulating EGFR transcription is upstream of AKT and thus affects the phosphorylation state of both the hydrophobic motif and activation loop of AKT, remains intact with the Leu1016Ser polymorphic variant of PHLPP2, does not depend on the PDZ ligand or PH domain, requires an intact LRR and nuclear localization, and dominates under agonist-evoked conditions. Our data reveal an additional tumor-suppressive role for PHLPP as a regulator of RTK levels, thus broadly controlling multiple oncogenic pathways downstream of RTKs.
PHLPP Suppresses Histone Acetylation and RTK Transcription. Analysis of tissue or MEFs from Phlpp1 −/− mice reveals that loss of PHLPP1 results in a robust increase in the steady-state levels of multiple RTKs, including the EGFR. Depletion of either PHLPP1 or PHLPP2 in both normal and cancer cell lines reveals that both PHLPP isozymes suppress RTK levels. Pharmacological analysis showed that the suppression of RTK levels by PHLPP is unlikely to be controlled by any of the known PHLPP substrates: Chronic inhibition of the three pathways (AKT, ERK, and PKC) currently known to be suppressed by PHLPP yielded no significant change in EGFR levels. Rather, RTK levels are regulated by a previously unidentified nuclear function of PHLPP in suppression of the acetylation of specific histones at specific sites. Rescue experiments reveal that the catalytic activity of PHLPP is required, as is the LRR domain; however the requirement for the LRR can be bypassed by forcing PHLPP into the nucleus by fusing an NLS on the protein. This nuclear localization is supported by previous fractionation studies showing PHLPP1 accumulation in the nucleus (47) and the ability to detect PHLPP1 at RTK promoters by ChIP assay. This nuclear-localized PHLPP suppresses acetylation of specific sites on the N-terminal tails of histones H2A, H2B, H3, and H4. At this point the mechanism for the PHLPP1-dependent increase in acetylation is unclear, but it is intriguing to note that these N-terminal tails are modified by phosphorylation. Thus, it will be of interest to determine whether PHLPP1 directly targets the phosphorylation of specific histone residues or influences the activity of histone acetyltransferases.
PHLPP as a Modifier of the Histone Code. Our data support a key role of PHLPP in modifying the histone code. Loss of PHLPP results in robust increases in phosphorylation and/or acetylation at specific sites on each of the four core histones. Whether these changes in the histone code result from direct dephosphorylation of residues such as S10 and S28 on H3 and S139 on H2A, in turn influencing acetylation at adjacent sites, remains to be elucidated. Indeed, molecular crosstalk is known to occur between histone phosphorylation and acetylation (18) . Notably, phosphorylation at S10 and T11 of H3 leads to an increase in acetylation at K9 and K14 (19, 48, 49) , as is consistent with our observation of coincident increases in phosphorylation on S10 and acetylation on K9 and K14 in cells lacking PHLPP1. The finding that PHLPP1 localizes at promoters whose transcription is suppressed by PHLPP but not at promoters whose transcription is not sensitive to PHLPP supports the possibility that PHLPP directly modifies histones on these promoters. Alternatively, PHLPP could dephosphorylate the writers or erasers that modify the code, thus modifying their function. Arguing against this notion is the finding that the effects of PHLPP are selective for certain promoters; one might have predicted less selectivity in the transcriptional target genes if PHLPP broadly regulated HDACs or histone acetyltransferases. Our data are consistent with a model in which PHLPP serves as an eraser of the histone code by dephosphorylating specific histone residues, in turn suppressing acetylation, and thus repressing transcription. Interestingly, it has been shown that stimulation with growth factors increases phosphorylation of histone H3 on S10, a modification that correlates with the transcriptional activation of immediate-early genes that lead to proto-oncogenic induction (50) . Our data suggest that PHLPP opposes this mechanism, contributing to its strong tumor-suppressive phenotype.
Tumor-Suppressive Function of PHLPP. Because RTKs are up-regulated in diverse cancers, receptor levels often serve as markers for tumor progression (51, 52), and designing drugs that inhibit the EGFR has become a major focus of cancer therapeutics in recent years (53, 54) . The identification of PHLPP as a master switch to control RTK levels is likely to be clinically relevant. Gene-expression studies have revealed that PHLPP1 and PHLPP2 expression is reduced in glioblastoma, providing a possible mechanism for the overexpression of EGFR in the absence of gene amplification (55) . Another EGFR family member, HER2, is frequently overexpressed in later-stage, more metastatic breast cancers in which PHLPP1 expression is reduced (56, 57) . The expression of the PHLPP isozymes is reduced in many tumor types and, in some cases, decreases as tumorigenesis progresses (57) (58) (59) . Consistent with this reduction, the ectopic expression of PHLPP in a glioblastoma and in a colon cancer cell line significantly reduced tumor growth in vivo in xenograft mouse models (24, 58) . Whether these tumor-suppressive effects of PHLPP are mediated directly by its regulation of growth factor receptor levels remains to be explored. Importantly, the dramatic effects of PHLPP on EGFR signaling place PHLPP at center stage as a global suppressor of oncogenic pathways.
Conclusion
The foregoing data show an even broader role for PHLPP as a tumor suppressor, beyond its role as a direct phosphatase for AKT, PKC, S6K, and Mst1, by suppressing the steady-state levels of RTKs, such as the EGFR, via its control of histone phosphorylation/ acetylation and hence transcription. Given the high up-regulation of multiple RTKs in cancers (3) , PHLPP may provide a pharmacological target to suppress levels of these oncogenic proteins effectively, particularly because the pharmacological profile of the upregulated receptor is unchanged. PHLPP is a more tenable pharmacological target than most other phosphatases because of its distinct structural composition with regulatory/targeting moieties encoded in the same polypeptide as the phosphatase domain.
Materials and Methods
Phlpp1
+/Δ heterozygous mice were intercrossed to isolate embryos and were used for Phlpp1 +/+ and Phlpp1 −/− fibroblast production, as described previously (60) . EGFR levels were analyzed in immortalized MEFs stably expressing various PHLPP constructs, mammalian cells overexpressing PHLPP1
and/or PHLPP2, or mammalian cells in which PHLPP1 and/or PHLPP2 were silenced by siRNA. A full description of biochemical and cell biological assays to probe EGFR function, stability, and turnover, as well as the methods used to detect mRNA levels and perform ChIP assays, can be found in SI Materials and Methods. ]methionine/cysteine (Met/Cys; 1,175 Ci/mmol) was purchased from PerkinElmer Life Sciences. Met/Cys-deficient DMEM was purchased from Invitrogen. Antibodies against Akt, phospho-Akt (pS473), ERK1/2, phospho-ERK1/2 (pT202/pY204), and EGF receptor and phospho-EGF receptor (Y1068) were purchased from Cell Signaling. HA antibodies were from Roche and Covance, and β-actin was from Sigma, Transferrin receptor antibody was from Zymed, and pan-ERK antibody was from BD. To pull down the EGF receptor from mouse embryonic fibroblast (MEF) lysates, an EGF receptor antibody from Santa Cruz (sc-03) was used. Antibodies against insulin receptor and PDGF receptor also were purchased from Santa Cruz. Pleckstrin homology (PH) domain leucine-rich repeat (LLR) protein phosphatase 1 (PHLPP1) and PHLPP2 antibodies were purchased from Bethyl Laboratories. PHLPP1 was detected in MEFs using an antibody raised against the previously described Cterminal segment of PHLPP1 (1) . The EGF receptor kinase activity reporter was a gift from Roger Tsien (UCSD) (2) . Antibodies against histones were purchased from Millipore and Cell Signaling.
MEF Production. Phlpp1
+/Δ mice were produced using the Cre/ LoxP system and are described elsewhere (3). Phlpp1
+/Δ heterozygous mice were intercrossed to isolate embryos and used for Phlpp1 +/+ and Phlpp1 −/− fibroblast production as previously described (4) . Animal protocols used in this study were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.
Cloning and Retroviral Infection. To reintroduce PHLPP1 into Phlpp1 −/− -knockout immortalized fibroblasts, HA-PHLPP1β was subcloned into BamHI and SalI sites of the retroviral vector pBABE-puro. Catalytically inactive HA-PHLPP1β (HA-PHLPP1β-D1413N) and deletion mutants of the PH domain (HA-PHLPP1β-ΔPH), the LRR-domain (HA-PHLPP1β-ΔLRR) and the PDZbinding motif (HA-PHLPP1β-ΔPDZ), as well as the nuclear localized (HA-NLS-PHLPP1 β) were generated by site-directed mutagenesis (Stratagene) in the retroviral vector pBABE-puro-HA-PHLPP1β. Phlpp1 −/− fibroblasts were infected using virus produced in HEK293 cells cotransfected with pBABE constructs and pcL10A vector (a kind gift from F. Furnari) using FuGENE 6 (Roche). Stable clones were selected using puromycin (1.5 μg/mL) and were tested for expression levels by Western blot. Levels of expression of PHLPP constructs in the Phlpp1 −/− MEFs were ∼10-fold higher than endogenous levels in the wild-type MEFs. MCF10A cells grown on plastic were infected with retroviral vector pSUPER (OligoEngine) or pSUPER-shPHLPP1 that contains the hairpin sequence ccGGAATCAACTGGTCACATTAGttcaagagaCTAATGTGACCAGTTGATTCCtt. Cells were selected using 1.5 μg/mL puromycin for 3 d and then were used in 3D cultures to stain surface EGF receptor by immunofluorescence as described for MCF10A in ref. 5 .
Cell Transfection and Western Blotting. Primary and immortalized
Phlpp1
+/+ and Phlpp1 −/− fibroblasts, LN444, and HeLa cells were maintained in DMEM (Cellgro) containing 10% (vol/vol) FBS and 1% penicillin/streptomycin at 37°C in 5% (vol/vol) CO 2 . MCF10A cells were maintained in DMEM/F12 (Cellgro) containing 5% (wt/vol) horse serum (Gibco), EGF (20 ng/mL) (Prepotech), hydrocortisone (5 μg/mL) (Sigma), cholera toxin (100 ng/mL) (Sigma), insulin (100 μg/mL) (Sigma), and 1% penicillin/ streptomycin at 37°C in 5% (vol/vol) CO 2 . siRNA was transfected into cells using Lipofectamine 2000 (Invitrogen), and the DNA encoding the EGF receptor kinase reporter was transfected into HeLa cells using FuGENE (Roche). For knockdown experiments with EGF treatment, cells were starved overnight (0.1% FBS) starting 48 h posttransfection. The following day, EGF (10 ng/mL) was added for the indicated times, and cells were collected. For overexpression experiments (EGF receptor kinase reporter experiments), cells were collected and imaged 24 h posttransfection. Before Western blotting, cells were lysed in a buffer containing 50 mM Na 2 HPO 4 (pH 7.5), 1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% SDS, 1 mM DTT, 200 μM benzamidine, 40 μg/mL leupeptin, and 1 mM phenylmethylsulfonyl fluoride and then were sonicated briefly. Lysates were separated by SDS/PAGE. When phospho-antibodies were used to probe the lysates, an equal amount of the lysate was run on a second gel and probed with the corresponding total protein antibody. For some experiments, cells were treated with cycloheximide (5 μM) for the indicated times, and EGF receptor levels were assessed by Western blot analysis of whole-cell lysates. For dose-response curves, Phlpp1 +/+ or Phlpp1 −/− MEFs were starved for 12 h, then were treated with 0-10 μM gefitinib (kind gift of Frank Furnari) for 4 h, and finally were treated with EGF (10 ng/mL) for 5 min. Phosphorylation of the EGF receptor (pY1068), total EGF receptor levels, phospho-ERK (pT202/pY204), and total ERK were determined by Western blot. Densitometric analysis was carried out with ImageJ software version 1.37v (6, 7).
Histone Extraction. For analysis of histone modifications, histone proteins were extracted from immortalized Phlpp +/+ and Phlpp −/− fibroblasts. Cells were harvested and washed with PBS supplemented with 5 mM sodium butyrate (Sigma), followed by lysis with Triton extraction buffer (PBS containing 0.5% Triton X-100, 1 μM Microcystin, 200 μM benzamidine, 1 mM Na 3 VO 4 , 40 μg/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride, and 20 mM β-glycerophosphate). Lysates were centrifuged, and histones were extracted overnight from pellets with 0.2N HCl. Histones extracts were centrifuged again to remove any residual pellet, and the pH was adjusted for Western blot. Histones extracts were separated by SDS/PAGE on Bis-Tris gels (BioRad).
Proliferation Assays. LN444 cells were transfected with control or PHLPP1 and PHLPP2 siRNA. Forty-eight hours posttransfection, cells were treated with DMSO, LY294002 (20 μM), U0126 (20 μM), or with both inhibitors for an additional 24 h. Cells were fixed in 70% (vol/vol) ice-cold methanol, collected, and stained with propidium iodide (25 μg/mL). Cell-cycle profiles were obtained via flow cytometric analysis with a Becton Dickinson FACSort. The crystal violet assay was used to measure the proliferation rate of Phlpp1 +/+ and Phlpp1 −/− fibroblasts. In brief, cells were plated in triplicate into 12-well plates (5,000-10,000 cells per well) and allowed to grow. At the indicated times, cells were fixed with ice-cold methanol and stained with a 0.2% crystal violet solution containing 20% (vol/vol) methanol in PBS. Plates were washed with deionized water and dried completely. Crystal violet absorbed by the cells was solubilized in 10% (vol/vol) acetic acid, and aliquots were measured in an ELISA plate reader at 595 nm.
Imaging EGF Receptor Kinase Activity. Cells were washed once in HBSS (Cellgro) and were imaged in HBSS in the dark at room temperature. Images were acquired on a Zeiss Axiovert microscope (Carl Zeiss Microimaging, Inc.) using a MicroMax digital camera (Roper-Princeton Instruments) controlled by MetaFluor software (Universal Imaging, Corp.). All optical filters were obtained from Chroma Technologies. Data were collected through a 10% neutral density filter. CFP and FRET images were obtained through a 420/20-nm excitation filter, a 450-nm dichroic mirror, and a 475/ 40-nm or 535/25-nm emission filter for CFP and FRET, respectively. A YFP image was obtained as a control for photobleaching through a 495/10-nm excitation filter, a 505-nm dichroic mirror, and a 535/ 25-nm emission filter. Excitation and emission filters were switched in filter wheels (Lambda 10-2)) (Sutter). Integration times were 200 ms for CFP and FRET and 100 ms for YFP.
Metabolic Labeling of the EGF Receptor. Phlpp1
+/+ and Phlpp1 −/− fibroblasts were incubated with DMEM without Met/Cys for 30 min at 37°C and then were incubated for the indicated times with DMEM containing 0.5 mCi/mL [ 35 S] Met/Cys at 37°C. Cells were lysed in buffer containing 50 mM Tris (pH 7.4), 100 mM NaCl, 1% Triton X-100, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 5 mM EDTA, 1 mM Na 3 VO 4 , and 1 mM phenylmethylsulfonyl fluoride. Lysates were cleared by centrifugation, and endogenous EGF receptor was immunoprecipitated from the supernatants by incubation with a polyclonal antibody from Santa Cruz overnight at 4°C. The immune complexes were recovered with Ultra-Link protein A/G beads, separated by SDS/PAGE, transferred to PVDF membranes, and analyzed by autoradiography. Densitometric analysis was performed using National Institutes of Health ImageJ analysis software. , and the levels of acetylated histones are shown (Right). The graph shows the mean ± SEM of quantified acetyl-histone levels from three independent experiments; **P < 0.001 and *P < 0.01 by Student t test.
